Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Key Points: Targeting RAD52 DNA binding domain I by peptide aptamer induces synthetic lethality in BRCA-deficient leukemias. Individual patients with BRCA-deficient leukemias could be identified by genetic and epigenetic profiling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences
Stark, J. M., Pierce, A. J., Oh, J., Pastink, A., & Jasin, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9305-9316.2004 · Cited by 501 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
Sallmyr, A., Fan, J., & Rassool, F. V. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.036 · Cited by 285 · cited 4×
“(F79), 4 mM ATRA (A), or F791ATRA or were left untreated (2).”
InfluentialSelf-citationRadiation-induced Assembly of Rad51 and Rad52 Recombination Complex Requires ATM and c-Abl
Chen, G., Yuan, S.-S. F., Liu, W., Xu, Y., Trujillo, K., Song, B., Cong, F., Goff, S. P., Wu, Y., Arlinghaus, R., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12748 · Cited by 274 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
Chun, J., Buechelmaier, E. S., & Powell, S. N. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00465-12 · Cited by 207 · cited 1×
“RAD52(1-212) protomer; the top and the bottom of the ssDNA binding groove are marked with arrows.”
Cited by
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Self-citationThe chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225
Self-citationAlves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Metadata
- Authors
- Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., Padget, M., Irvine, D. A., Sliwinski, T., Haas, K., Lee, J., Geng, H., Roy, D., Slupianek, A., Rassool, F. V., Wasik, M. A., Childers, W., Copland, M., Müschen, M., Civin, C. I., & Skorski, T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-15
- Volume
- 122
- Issue
- 7
- Pages
- 1293-1304
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2025329130
- Cited by
- 145
- References
- 10
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. https://app.cochat.ai/papers/10.1182/blood-2013-05-501072
- The paper
- Cramer-Morales, K., Nieborowska-Skorska, M., Scheibner, K., Padget, M., Irvine, D. A., Sliwinski, T., Haas, K., Lee, J., Geng, H., Roy, D., Slupianek, A., Rassool, F. V., Wasik, M. A., Childers, W., Copland, M., Müschen, M., Civin, C. I., & Skorski, T. (2013). Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. https://doi.org/10.1182/blood-2013-05-501072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.